Smiths Detection Hold Baggage Screening Technology to Support Upgrade to ECAC Standard 3 EDS at Munich Airport
Smiths Detection has been selected by the District Government of Upper Bavaria to supply ECAC Standard 3 EDS hold baggage screening systems to Munich Airport. The contract comprises 25 x HI-SCAN 10080 XCT advanced scanners which amalgamate high resolution X-ray technology, computed tomography (CT) and advanced detection algorithms to deliver exceptional levels of security whilst also increasing operational efficiency. A service agreement is also included.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171010005842/en/
HI-SCAN 10080 XCT advanced hold baggage scanners (Photo: Business Wire)
The scanners will not only detect the explosives threats specified by the new standard, but can also be easily upgraded to meet future requirements to identify evolving threats. Combining a very fast belt speed with a large rectangular tunnel, they offer a continuously high throughput of up to 1,800 bags per hour. Extremely sharp, full colour, high resolution images, as well as a low false alarm rate also support the greater levels of efficiency required by the new regulations.
Munich is Germany’s second largest airport and the only one in Europe to be awarded 5-star status in the Skytrax World Airport Rating. It already handles 100 airlines flying to over 250 destinations in over 70 countries with plans for further development. The new technology will deliver the efficiencies required by such a busy hub both now and in the future.
“We welcome the opportunity to help airports in upgrading to ECAC Standard 3. It is a major step but the rewards are significant in terms of higher levels of security and operational efficiency,” explained Tony Tielen, VP EMEA for Smiths Detection. “The new equipment will be seamlessly integrated into Munich Airport’s existing infrastructure to ensure smooth ongoing service during the upgrade.”
To be deployed in both terminals, the first three scanners will be installed and fully operational by the end of this year. The remaining installations will be progressively rolled out between 2018 and 2021. Also included in the deal are 49 Level 2 and 3 workstations and a Matrix Server.
Notes to editors
HI-SCAN 10080 XCT key features:
- EU/ECAC EDS Standard 3 approved
- Laboratory certified for high-speed checked baggage screening by the United States Transportation Security Administration (TSA)
- Belt speed of 0.5m/sec (98.5ft/min)
- High throughput of up to 1800 bags per hour
- Large tunnel capable of screening objects 100 x 80 cm (39.4 x 31.5in)
A dual-energy X-ray line scanner with full 3D volumetric Computed Tomography (CT) imaging and reconstruction, the HI-SCAN 10080 XCT is the next generation high-speed checked baggage explosives detection system (EDS).
With a belt speed of 0.5m/sec (98.5ft/min) and a large 1070 x 810mm (42.1 x 31.9in) rectangular tunnel, the HI-SCAN 10080 XCT provides the most economical solution for airport checked baggage screening requirements. This combination of belt speed and tunnel size will provide baggage handling systems the capability to process a throughput of up to 1800 bags/hour with object sizes of up to 1000 x 800 mm (39.4 x 31.5in).
The HI-SCAN 10080 XCT is designed to integrate easily into newly implemented Hold Baggage System (HBS) configurations or as a replacement for current baggage handling systems.
Further details on the Smiths Detection HI-SCAN 10080 XCT can be found here: http://www.smithsdetection.com/index.php?option=com_k2&view=item&id=157:hi-scan-10080-xct&Itemid=101&lang=en#.WKwoEoXXLmg
About Smiths Detection
Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and military markets. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
Our goal is simple – to provide security, peace of mind and freedom of movement upon which the world depends. For more information visit www.smithsdetection.com
Global Aviation Marketing Director
+49 (0)611 9412 422
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an